<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管高季刊</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U -NV u8003KrCpq8yLQC-&amp;ff=20230818021019&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_source =镀铬<description>心血管高季刊：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230818021019&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 8 月 18 日星期五 06:10:20 +0000</lastbuilddate><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>建立功能分离的多巴胺能突触的投射特异性信号</title><link/>https://pubmed.ncbi.nlm.nih.gov/37591240/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230818021019&amp;v=2.17.9.post6+86293ac<description>多巴胺能投射不同程度地调节大脑功能，并与许多神经精神疾病有关。有两种解剖学和功能上不同的多巴胺能投射连接中脑和纹状体：黑质纹状体，控制运动，中脑边缘，调节动机。是否建立尚不清楚。通过公正的研究搜索后，我们确定了两组拮抗的 TGF-β 家族成员，骨... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 9 日：S0092-8674(23)00801-2.doi: 10.1016/j.cell.2023.07.023.打印前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">多巴胺能投射不同程度地调节大脑功能，并与许多神经精神疾病有关。有两种解剖学和功能上不同的多巴胺能投射连接中脑和纹状体：黑质纹状体，控制运动，中脑边缘，调节动机。是否建立尚不清楚。分别是神经元.其受体的投射优先表达有助于特定的突触发育。下游，Smad1 和 Smad2 被特异性激活，并且是黑质纹状体与中脑边缘投射中多巴胺能突触发育和功能所必需的。值得注意的是，Smad1 突变小鼠表现出运动缺陷，而 Smad2 突变小鼠则表现出运动缺陷这些结果揭示了功能分离的多巴胺能突触正确建立的分子逻辑，并可能提供通过靶向特定 BMP/TGF-β 和/或 Smad 来治疗相关的、预测特异性疾病症状的策略。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37591240/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37591240</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.07.023>10.1016/j.cell.2023.07.023</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37591240</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:creator>寺内明子</dc:creator><dc:creator>叶帕特里夏</dc:creator><dc:creator>艾琳·约翰逊·文卡特什</dc:creator><dc:creator>马里尔·塞利尔</dc:creator><dc:creator>丽莎·金</dc:creator><dc:creator>朱莉娅·C·皮蒂诺</dc:creator><dc:creator>伊莱·克里泽</dc:creator><dc:creator>张启宇</dc:creator><dc:creator>周杰</dc:creator><dc:creator>李玉龙</dc:creator><dc:creator>大卫·D·金蒂</dc:creator><dc:creator>李伟忠</dc:creator><dc:creator>梅森尚</dc:creator><dc:date>2023-08-17</dc:date><dc:source>细胞</dc:source><dc:title>建立功能分离的多巴胺能突触的投射特异性信号</dc:title><dc:identifier>下午：37591240</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.023</dc:identifier></item><item><title>衰老小鼠大脑图谱揭示白质是脆弱的焦点</title><link/>https://pubmed.ncbi.nlm.nih.gov/37591239/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230818021019&amp;v=2.17.9.post6+86293ac<description>衰老是认知能力下降的关键风险因素，但人们对大脑衰老背后的分子变化仍知之甚少。在这里，我们对小鼠大脑进行了时空 RNA 测序，对来自 7 个年龄段 15 个区域的 1,076 个样本进行了分析，并进行了 2 次年轻化干预。神经胶质细胞衰老的广泛基因特征，表现出空间上定义的幅度变化。通过整合空间和单核转录组学，我们发现神经胶质细胞... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 8 月 8 日：S0092-8674(23)00805-X.doi：10.1016/j.cell.2023.07.027.打印前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">衰老是认知能力下降的关键风险因素，但人们对大脑衰老背后的分子变化仍知之甚少。在这里，我们对小鼠大脑进行了时空 RNA 测序，对来自 7 个年龄段 15 个区域的 1,076 个样本进行了分析，并进行了 2 次年轻化干预。神经胶质细胞衰老的广泛基因特征，表现出空间上定义的幅度变化。通过整合空间和单核转录组学，我们发现与皮质区域相比，白质中的神经胶质细胞衰老特别加速，而特殊的神经元群体则表现出区域特异性表达变化。年轻化干预措施，包括年轻血浆注射和饮食限制，对特定大脑区域的基因表达表现出明显的影响。这是疾病的潜在调节剂。我们的研究结果确定了大脑衰老的分子焦点，为针对与年龄相关的认知衰退提供了基础。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37591239/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37591239</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.07.027>10.1016/j.cell.2023.07.027</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37591239</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:creator> ——奥利弗·哈恩</dc:creator><dc:creator>奥尔登·G·福尔茨</dc:creator><dc:creator>米凯亚·阿特金斯</dc:creator><dc:creator>布伦·凯迪尔</dc:creator><dc:creator>帕特里夏·莫兰-洛萨达</dc:creator><dc:creator>——伊恩·H·古德纳</dc:creator><dc:creator>克里斯蒂·蒙森</dc:creator><dc:creator>法比安·克恩 (Fabian Kern)</dc:creator><dc:creator>罗伯特·帕洛维奇</dc:creator><dc:creator>南南路</dc:creator><dc:creator>张慧</dc:creator><dc:creator>阿金特·考尔</dc:creator><dc:creator>雅各布·赫尔</dc:creator><dc:creator>约翰·R·胡根纳德</dc:creator><dc:creator>塞巴斯蒂安·格伦克</dc:creator><dc:creator>伯努瓦·勒哈利尔</dc:creator><dc:creator>琳达·帕特里奇</dc:creator><dc:creator>安德烈亚斯·凯勒</dc:creator><dc:creator>托尼·维斯-科雷</dc:creator><dc:date>2023-08-17</dc:date><dc:source>细胞</dc:source><dc:title>衰老小鼠大脑图谱揭示白质是脆弱的焦点</dc:title><dc:identifier>下午：37591239</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.027</dc:identifier></item><item><title>心房颤动的组织病理学：这是否有助于我们了解其发病机制？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37590445/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230818021019&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 8 月 17 日：ehad515。doi：10.1093/eurheartj/ehad515。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37590445/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37590445</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad515>10.1093/eurheartj/ehad515</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37590445</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:creator>川上梨花</dc:creator><dc:creator>阿洛克诉芬恩</dc:creator><dc:creator>雷努·维尔马尼</dc:creator><dc:date>2023-08-17</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>心房颤动的组织病理学：这是否有助于我们了解其发病机制？</dc:title><dc:identifier>下午：37590445</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad515</dc:identifier></item><item><title> Danicamtiv 招募肌球蛋白马达来帮助衰竭的心脏</title><link/>https://pubmed.ncbi.nlm.nih.gov/37590375/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230818021019&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 18 日；133(5):444-446。doi: 10.1161/CIRCRESAHA.123.323366。Epub 2023 年 8 月 17 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37590375/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37590375</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323366>10.1161/CIRCRESAHA.123.323366</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37590375</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:creator>麦孔·兰迪姆-维埃拉</dc:creator><dc:creator>比约恩·C·诺尔曼</dc:creator><dc:date>2023-08-17</dc:date><dc:source>流通研究</dc:source><dc:title>Danicamtiv 招募肌球蛋白马达来帮助衰竭的心脏</dc:title><dc:identifier>下午：37590375</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323366</dc:identifier></item><item><title>认识第一作者</title><link/>https://pubmed.ncbi.nlm.nih.gov/37590374/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230818021019&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 18 日；133(5):374-375。doi: 10.1161/RES.0000000000000629。Epub 2023 年 8 月 17 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37590374/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37590374</a> | DOI： <a href=https://doi.org/10.1161/RES.0000000000000629>10.1161/RES.0000000000000629</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37590374</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:date> 2023-08-17</dc:date><dc:source>流通研究</dc:source><dc:title>认识第一作者</dc:title><dc:identifier>下午：37590374</dc:identifier><dc:identifier> doi:10.1161/RES.0000000000000629</dc:identifier></item><item><title>内皮 FIS1 去SUMO化可预防缺氧性肺动脉高压</title><link/>https://pubmed.ncbi.nlm.nih.gov/37589160/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230818021019&amp;v=2.17.9.post6+86293ac<description>结论：通过内皮线粒体稳态，FIS1 的去 SUMO 化可适应性地保护肺内皮功能免受缺氧应激，从而预防 PH。肺内皮中的 FIS1 去 SUMO 化-SUMO 化转变是缺氧 PH 的内在发病机制。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 8 月 17 日。doi：10.1161/CIRCRESAHA.122.321200。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：缺氧是肺动脉高压（PH）的主要原因和促进者，肺动脉高压是一种典型的血管重塑疾病，预后差，死亡率高。先前的临床研究和我们的研究结果表明，内皮线粒体翻译后 SUMO 化在缺氧相关血管病变中具有潜在作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：采用慢性缺氧小鼠模型和Sugen/缺氧大鼠模型作为PH动物模型，通过透射电子显微镜和免疫荧光显微镜测定线粒体形态和亚细胞结构，通过线粒体耗氧率和细胞外酸化率测定线粒体代谢。通过免疫沉淀测定相互作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在缺氧相关PH的临床标本中发现了SENP1（sentrin特异性蛋白酶1）介导的SUMO化参与肺内皮线粒体重塑，并在缺氧条件下的人肺动脉内皮细胞中得到了验证。 PH模型、人肺动脉内皮细胞和人胚胎干细胞来源的内皮细胞表明，短期缺氧诱导SENP1易位至内皮线粒体，调节线粒体裂变蛋白FIS1（线粒体裂变1）的去SUMO化，从而促进FIS1与融合蛋白 MFN2（线粒体融合蛋白 2）和线粒体看门人 VDAC1（电压依赖性阴离子通道 1），以及通过增强其寡聚化来增强 MFN2 的膜束缚活性。跨线粒体相关膜的钙通讯，随后保持肺内皮功能和血管稳态。 ，在小鼠的肺内皮中引入病毒包装的去SUMO化的FIS1改善了肺内皮功能障碍和缺氧PH的发展，而在小鼠中敲入SUMO（小泛素样修饰剂）缀合的FIS1则夸大了患病的细胞和组织表型。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：通过内皮线粒体稳态，FIS1 的去 SUMO 化可适应性地保护肺内皮功能免受缺氧应激，从而预防 PH。肺内皮中的 FIS1 去 SUMO 化-SUMO 化转变是缺氧 PH 的内在发病机制。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37589160/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37589160</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.122.321200>10.1161/CIRCRESAHA.122.321200</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37589160</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:creator>周晓飞</dc:creator><dc:creator>蒋元庆</dc:creator><dc:creator>王跃文</dc:creator><dc:creator>林格范</dc:creator><dc:creator>朱云辉</dc:creator><dc:creator>陈业峰</dc:creator><dc:creator>王怡然</dc:creator><dc:creator>朱英仪</dc:creator><dc:creator>王宏坤</dc:creator><dc:creator>潘子航</dc:creator><dc:creator>李周斌</dc:creator><dc:creator>朱小龙</dc:creator><dc:creator>任瑞哲</dc:creator><dc:creator>真哥</dc:creator><dc:creator>赖东武</dc:creator><dc:creator>赖恩银</dc:creator><dc:creator>陈婷</dc:creator><dc:creator>王凯</dc:creator><dc:creator>梁平</dc:creator><dc:creator>秦凌峰</dc:creator><dc:creator>刘翠清</dc:creator><dc:creator>丛秋</dc:creator><dc:creator>迈克尔·西蒙斯</dc:creator><dc:creator>鲁阳宇</dc:creator><dc:date>2023-08-17</dc:date><dc:source>流通研究</dc:source><dc:title>内皮 FIS1 去SUMO化可预防缺氧性肺动脉高压</dc:title><dc:identifier>下午：37589160</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.122.321200</dc:identifier></item><item><title>瓣膜外心肌损伤和主动脉瓣置换术</title><link/>https://pubmed.ncbi.nlm.nih.gov/37587588/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230818021019&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 22 日；82(8):e67.doi: 10.1016/j.jacc.2023.04.061。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37587588/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37587588</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.04.061>10.1016/j.jacc.2023.04.061</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37587588</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:creator>艾哈迈德·埃尔卡里奥尼</dc:creator><dc:date>2023-08-17</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>瓣膜外心肌损伤和主动脉瓣置换术</dc:title><dc:identifier>下午：37587588</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.04.061</dc:identifier></item><item><title>奥林匹克耐力运动员右心室重构的长期临床后果</title><link/>https://pubmed.ncbi.nlm.nih.gov/37587587/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230818021019&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 22 日；82(8):750-751.doi:10.1016/j.jacc.2023.04.060。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37587587/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37587587</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.04.060>10.1016/j.jacc.2023.04.060</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37587587</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:creator>安东尼奥·佩利西亚</dc:creator><dc:creator>罗伯托·费拉拉</dc:creator><dc:creator>西尔维娅·普罗斯佩里</dc:creator><dc:creator>安东尼奥·斯帕塔罗</dc:creator><dc:creator>维维安娜·梅斯特里尼</dc:creator><dc:creator>玛丽亚·罗萨里亚·斯奎奥</dc:creator><dc:date>2023-08-17</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>奥林匹克耐力运动员右心室重构的长期临床后果</dc:title><dc:identifier>下午：37587587</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.04.060</dc:identifier></item><item><title>科学、健康和教育作为进步的贡献者所面临的挑战：对年轻一代的呼吁</title><link/>https://pubmed.ncbi.nlm.nih.gov/37587586/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230818021019&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 22 日；82(8):748-749.doi:10.1016/j.jacc.2023.07.002。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37587586/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37587586</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.002>10.1016/j.jacc.2023.07.002</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37587586</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:creator>瓦伦丁·福斯特</dc:creator><dc:creator>——贾斯汀·瓦里尔·图尔科</dc:creator><dc:date>2023-08-17</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>科学、健康和教育作为进步的贡献者所面临的挑战：对年轻一代的呼吁</dc:title><dc:identifier>下午：37587586</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.002</dc:identifier></item><item><title>非缺血性心肌病患者心律失常死亡的风险：JACC 本周评论主题</title><link/>https://pubmed.ncbi.nlm.nih.gov/37587585/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230818021019&amp;v=2.17.9.post6+86293ac<description>非缺血性心肌病 (NICM) 很常见，患者因室性心律失常而面临早期死亡的显着风险。当前指南建议采用植入式心律转复除颤器 (ICD) 治疗来减少心力衰竭和左心室射血减少患者的心源性猝死 (SCD)然而，在仅由 NICM 患者组成的随机临床试验中，一级预防 ICD 并未带来显着的死亡率益处。此外，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 22 日；82(8):735-747.doi:10.1016/j.jacc.2023.05.064。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">非缺血性心肌病 (NICM) 很常见，患者因室性心律失常而面临早期死亡的显着风险。当前指南建议采用植入式心律转复除颤器 (ICD) 治疗来减少心力衰竭和左心室射血减少患者的心源性猝死 (SCD)然而，在仅由 NICM 患者组成的随机临床试验中，一级预防 ICD 并未带来显着的死亡率益处。此外，左心室射血分数对于预测 SCD 的敏感性和特异性有限。对于 SCD 风险最高的患者。SCD 的计算模型风险分层，并提出新策略来指导未来对 NICM 患者进行 SCD 风险评估的临床试验。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37587585/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37587585</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.064>10.1016/j.jacc.2023.05.064</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37587585</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:creator>乔纳森·克里斯平</dc:creator><dc:creator>费萨尔·M·麦钱特</dc:creator><dc:creator>Neal K Lakdawala更多</dc:creator><dc:creator>凯瑟琳·吴</dc:creator><dc:creator>——戈登·F·托马塞利</dc:creator><dc:creator>拉奇塔·纳瓦拉</dc:creator><dc:creator>埃斯特尔·托贝</dc:creator><dc:creator>阿姆鲁特·V·安巴德卡</dc:creator><dc:creator>拉杰什·卡布拉</dc:creator><dc:creator>埃洛伊莎·阿布斯蒂尼</dc:creator><dc:creator>贾加特·纳鲁拉</dc:creator><dc:creator>玛雅·古格林</dc:creator><dc:creator>克里斯汀·M·阿尔伯特</dc:creator><dc:creator>苏米特·楚格</dc:creator><dc:creator>娜塔莉亚·特拉亚诺娃</dc:creator><dc:creator>吉姆·W·张</dc:creator><dc:date>2023-08-17</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>非缺血性心肌病患者心律失常死亡的风险：JACC 本周评论主题</dc:title><dc:identifier>下午：37587585</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.064</dc:identifier></item><item><title> ACC/AHA 和 ESC/EACTS 瓣膜性心脏病管理指南：JACC 指南比较</title><link/>https://pubmed.ncbi.nlm.nih.gov/37587584/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230818021019&amp;v=2.17.9.post6+86293ac<description>瓣膜性心脏病 (VHD) 很常见，从诊断和治疗管理的角度来看，它提出了重要的挑战。临床实践指南的制定旨在帮助医疗保健专业人员克服这些挑战，并为 VHD 患者提供最佳的治疗。美国心脏病学会与美国心脏协会、欧洲心脏病学会合作，与欧洲心胸协会合作…… </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 22 日；82(8):721-734.doi:10.1016/j.jacc.2023.05.061。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">瓣膜性心脏病 (VHD) 很常见，从诊断和治疗管理的角度来看，它提出了重要的挑战。临床实践指南的制定旨在帮助医疗保健专业人员克服这些挑战，并为 VHD 患者提供最佳的治疗。美国心脏病学会与美国心脏协会、欧洲心脏病学会以及欧洲心胸外科协会合作，最近更新了他们的 VHD 管理指南。代表 EuroValve 联盟编写的这篇评论描述了一致性以及指南之间的差异，并强调了这些指南中的差距以及填补这些差距的未来研究前景。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37587584/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37587584</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.061>10.1016/j.jacc.2023.05.061</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37587584</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:creator>奥古斯丁·科瓦纳</dc:creator><dc:creator>帕特里齐奥·兰切洛蒂</dc:creator><dc:creator>吉尔伯特·哈比卜</dc:creator><dc:creator>马达琳娜·加尔比</dc:creator><dc:creator>乔迪·桑切斯·达尔</dc:creator><dc:creator>Marco Barbanti更多</dc:creator><dc:creator>Mani A Vannan更多</dc:creator><dc:creator>瓦西里奥斯·瓦西里乌</dc:creator><dc:creator>达里乌什·杜德克</dc:creator><dc:creator>奥维迪乌·奇翁塞尔</dc:creator><dc:creator>约翰内斯·L·瓦尔滕伯格</dc:creator><dc:creator>维多利亚·约翰逊</dc:creator><dc:creator>鲁杰罗·德保利斯</dc:creator><dc:creator>鲁道夫·西特罗</dc:creator><dc:creator>菲利普·皮瓦罗</dc:creator><dc:creator>欧洲阀门联盟</dc:creator><dc:date>2023-08-17</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>ACC/AHA 和 ESC/EACTS 瓣膜性心脏病管理指南：JACC 指南比较</dc:title><dc:identifier>下午：37587584</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.061</dc:identifier></item><item><title>右心房作为毛细血管前性肺动脉高压右心室僵硬度和治疗反应的晴雨表</title><link/>https://pubmed.ncbi.nlm.nih.gov/37587583/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230818021019&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 22 日；82(8):718-720.doi:10.1016/j.jacc.2023.06.009。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37587583/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37587583</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.009>10.1016/j.jacc.2023.06.009</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37587583</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:creator>玛丽亚·罗莎·科斯坦佐</dc:creator><dc:creator>——托马斯·H·马维克</dc:creator><dc:date>2023-08-17</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>右心房作为毛细血管前性肺动脉高压右心室僵硬度和治疗反应的晴雨表</dc:title><dc:identifier>下午：37587583</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.009</dc:identifier></item><item><title>右心房对毛细血管前肺动脉高压的适应：压力容积、心肌细胞和组织学分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/37587582/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230818021019&amp;v=2.17.9.post6+86293ac<description>结论：RA PV 环显示 RA 僵硬度增加，提示严重 RV 舒张期僵硬度患者房室不偶联。precPH 患者分离的 RA 心肌细胞肥大，但无内在肌节变化。在终末期 precPH 中，毛细血管密度降低，伴有间质和血管周围的心肌细胞肥大。纤维化。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 22 日；82(8):704-717.doi:10.1016/j.jacc.2023.05.063。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：毛细血管前肺动脉高压（precPH）患者的右心房（RA）功能和右心室（RV）舒张期僵硬度发生改变。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究旨在利用压力-容积 (PV) 环、分离的心肌细胞和组织学分析来研究 RA 功能。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用磁共振和导管数据在对照受试者（n = 9）和 precPH 患者（n = 27）中构建 RA PV 环。RA 硬度（心房充盈期间的压力上升）和右房室耦合指数（RA 最小容积 / RV）在具有中度 (n = 39) 或重度 (n = 41) RV 舒张僵硬度的较大队列患者中进行比较。从对照组 (n = 6) 和 precPH 患者 (n = 6) 收集的 RA 组织中分离出心肌细胞 ( n = 9) 接受手术。从对照受试者 (n = 6) 和 precPH 患者 (n = 4) 中收集尸检材料，以研究 RA 肥大、毛细血管化和纤维化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：RA PV 环显示 3 个 RA 心脏时相（储备期、被动排空期和收缩期），伴有 precPH 扩张和压力升高。具有严重 RV 舒张期僵硬度的 PrecPH 患者 RA 僵硬度增加，右房室耦合指数更差。 precPH 增加 2 至 3 倍<sup>，</sup>但肌节产生的主动张力未改变。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：RA PV 环显示 RA 僵硬度增加，提示严重 RV 舒张期僵硬度患者房室不偶联。precPH 患者分离的 RA 心肌细胞肥大，但无内在肌节变化。在终末期 precPH 中，毛细血管密度降低，伴有间质和血管周围的心肌细胞肥大。纤维化。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37587582/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37587582</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.063>10.1016/j.jacc.2023.05.063</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37587582</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:creator>杰罗恩·韦塞尔斯</dc:creator><dc:creator>——杰西·范·韦森贝克</dc:creator><dc:creator>雅里·德·罗弗</dc:creator><dc:creator>罗文·斯莫尔</dc:creator><dc:creator>阿伊达·卢西亚-巴尔德佩拉斯</dc:creator><dc:creator>卢卡斯·R·切兰特</dc:creator><dc:creator>J蒂姆·马库斯</dc:creator><dc:creator>——莉莲·J·梅杰布姆</dc:creator><dc:creator>乔安妮·格罗内维尔特</dc:creator><dc:creator>——弗兰克·PT·奥斯特维尔</dc:creator><dc:creator>卡通温克尔曼</dc:creator><dc:creator>汉斯·尼森</dc:creator><dc:creator>玛丽·何塞·古曼</dc:creator><dc:creator>Harm Jan Bogaard更多</dc:creator><dc:creator>安东·冯克·诺德赫拉夫</dc:creator><dc:creator>古斯塔夫·J·斯特莱克斯</dc:creator><dc:creator>M路易斯·汉多科</dc:creator><dc:creator>贝伦德·韦斯特霍夫</dc:creator><dc:creator>弗朗西斯·S·德曼</dc:creator><dc:date>2023-08-17</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>右心房对毛细血管前肺动脉高压的适应：压力容积、心肌细胞和组织学分析</dc:title><dc:identifier>下午：37587582</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.063</dc:identifier></item><item><title>当降级至替格瑞洛单药治疗时，出血和缺血事件的风险分层是否仍然有用？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37587581/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230818021019&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 22 日；82(8):701-703.doi:10.1016/j.jacc.2023.06.010。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37587581/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37587581</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.010>10.1016/j.jacc.2023.06.010</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37587581</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:creator>普加·B·帕里克</dc:creator><dc:creator>图利奥·帕尔梅里尼</dc:creator><dc:date>2023-08-17</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>当降级至替格瑞洛单药治疗时，出血和缺血事件的风险分层是否仍然有用？</dc:title><dc:identifier>下午：37587581</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.010</dc:identifier></item><item><title>冠状动脉介入治疗后替格瑞洛单药治疗的出血和缺血风险</title><link/>https://pubmed.ncbi.nlm.nih.gov/37587580/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230818021019&amp;v=2.17.9.post6+86293ac<description>结论：与继续 DAPT 相比，PCI 后三个月，停用阿司匹林并维持替格瑞洛单药治疗可减少出血风险较高和出血风险较低的患者的出血。单独用于冠状动脉介入治疗后的高风险患者 [TWILIGHT]；NCT02270242）。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 22 日；82(8):687-700.doi:10.1016/j.jacc.2023.05.062。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：Twilight（冠状动脉介入治疗后高危患者中替格瑞洛联合阿司匹林或单用），在接受经皮冠状动脉介入治疗（PCI）的高危患者中，替格瑞洛单药治疗与完成后继续阿司匹林和替格瑞洛双重抗血小板治疗（DAPT）的比较为期 3 个月的 DAPT 疗程可减少出血，但不会增加缺血事件。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究旨在通过对个体患者的相关潜在出血益处和缺血性危害同时建模，研究替格瑞洛单一疗法与 DAPT 相比的临床益处。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：多变量 Cox 回归模型用于：1) 出血学术研究联盟 2、3 或 5 型 (BARC-2/3/5)；2) 心血管死亡、非致命性心肌梗塞和非致命性缺血性中风（主要不良心脏和脑血管事件[MACCE]）是使用逐步前向变量选择开发的。）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在整个研究组（N = 7,119）中，391 名患者（5.5%）发生了 BARC-2/3/5，258 名患者（3.6%）发生了 MACCE。替格瑞洛相关的出血事件持续减少. 单一疗法与 DAPT 在出血和缺血风险层中的比较（P 相互作用分别 = 0.54 和 0.11）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与继续 DAPT 相比，PCI 后三个月，停用阿司匹林并维持替格瑞洛单药治疗可减少出血风险较高和出血风险较低的患者的出血。单独用于冠状动脉介入治疗后的高风险患者 [TWILIGHT]；NCT02270242）。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37587580/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37587580</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.062>10.1016/j.jacc.2023.05.062</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37587580</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:creator>吉奥马尔·门迭塔</dc:creator><dc:creator>沙米尔·梅赫塔</dc:creator><dc:creator>乌斯曼·巴贝尔</dc:creator><dc:creator>多米尼克·J·安吉奥利洛</dc:creator><dc:creator>卡罗·布里古里</dc:creator><dc:creator>大卫·科恩</dc:creator><dc:creator>蒂莫西·科利尔</dc:creator><dc:creator>乔治·丹加斯</dc:creator><dc:creator>达里乌什·杜德克</dc:creator><dc:creator>哈维尔扫描</dc:creator><dc:creator>罗伯特·吉尔</dc:creator><dc:creator>比尔吉特·沃格尔</dc:creator><dc:creator>曹大卫</dc:creator><dc:creator>亚历山德罗·斯皮里托</dc:creator><dc:creator>库尔特·胡贝尔</dc:creator><dc:creator>阿德南·卡斯特拉蒂</dc:creator><dc:creator>乌彭德拉·考尔</dc:creator><dc:creator>兰·科诺夫斯基</dc:creator><dc:creator>——米切尔·W·克鲁科夫</dc:creator><dc:creator>Vijay Kunadian更多</dc:creator><dc:creator>大卫·J·莫莱特诺</dc:creator><dc:creator>马格努斯·欧曼</dc:creator><dc:creator>根纳罗·萨德拉</dc:creator><dc:creator>萨曼莎·萨托里</dc:creator><dc:creator>萨明·夏尔马</dc:creator><dc:creator>——理查德·什洛夫米茨</dc:creator><dc:creator>加布里埃尔·斯泰格</dc:creator><dc:creator>韩雅玲</dc:creator><dc:creator>斯图尔特·波科克</dc:creator><dc:creator>C迈克尔·吉布森</dc:creator><dc:creator>罗克珊娜·迈赫兰</dc:creator><dc:date>2023-08-17</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>冠状动脉介入治疗后替格瑞洛单药治疗的出血和缺血风险</dc:title><dc:identifier>下午：37587580</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.062</dc:identifier></item><item><title>长时间太空飞行与心脏形态：大胆前往前人未曾去过的地方</title><link/>https://pubmed.ncbi.nlm.nih.gov/37587579/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230818021019&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 22 日；82(8):685-686.doi:10.1016/j.jacc.2023.06.030。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37587579/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37587579</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.06.030>10.1016/j.jacc.2023.06.030</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37587579</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Carl L Tommaso更多</dc:creator><dc:date>2023-08-17</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>长时间太空飞行与心脏形态：大胆前往前人未曾去过的地方</dc:title><dc:identifier>下午：37587579</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.06.030</dc:identifier></item><item><title>长时间太空飞行对心脏的影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/37587578/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230818021019&amp;v=2.17.9.post6+86293ac<description>结论：在长时间的太空飞行中，尽管心脏总做功总体减少，但目前国际空间站上使用的运动对策似乎可以有效抵消心脏质量和体积的减少。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 22 日；82(8):674-684.doi:10.1016/j.jacc.2023.05.058。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：心室质量对体力活动和负荷的变化做出反应，运动训练后心脏肥大，持续不活动后心脏萎缩。微重力期间心室壁应力（即负荷）减少。模拟微重力 12 周期间，心脏萎缩不会趋于稳定。但可以通过同时进行运动训练来缓解。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：本研究的目的是确定国际空间站（ISS）当前的运动对策是否可以抵消长时间太空飞行期间的心脏萎缩。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们测量了 13 名宇航员（4 名女性；年龄 49 ± 4 岁）的左心室 (LV) 和右心室 (RV) 质量和体积（通过磁共振成像），测量时间为 155 ±此外，我们还评估了太空飞行前 21 至 7 天以及任务结束前 15 天的总心脏做功，并通过配对样本 t 检验对数据进行了比较。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：太空飞行期间总心脏做功较低 (P = 0.008)；然而，我们观察到飞行后 LV 质量没有显着差异（飞行前：115 ± 30 g vs 飞行后：118 ± 29 g；P = 0.053），略高左心室每搏输出量 (P = 0.074) 和飞行后射血分数 (P = 0.075)。右心室质量 (P = 0.999)、右心室射血分数 (P = 0.147) 以及心室舒张末期 (P = 0.934) 和收缩末期容积(P = 0.145) 飞行后没有差异。左心室质量的相对变化与总心输出量 (r = 0.73; P = 0.015) 和总心脏做功 (r = 0.53; P = 0.112）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在长时间的太空飞行中，尽管心脏总做功总体减少，但目前国际空间站上使用的运动对策似乎可以有效抵消心脏质量和体积的减少。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37587578/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37587578</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.058>10.1016/j.jacc.2023.05.058</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37587578</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:creator>柴田茂树</dc:creator><dc:creator>丹尼斯·韦克汉姆</dc:creator><dc:creator>詹姆斯·D·托马斯</dc:creator><dc:creator>舒阿布·M·阿卜杜拉</dc:creator><dc:creator>史蒂文·普拉茨</dc:creator><dc:creator>迈克尔·W·邦戈</dc:creator><dc:creator>本杰明·D·莱文</dc:creator><dc:date>2023-08-17</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>长时间太空飞行对心脏的影响</dc:title><dc:identifier>下午：37587578</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.058</dc:identifier></item><item><title>患有遗传性心脏病的运动员参加竞技体育：一种全新的球赛</title><link/>https://pubmed.ncbi.nlm.nih.gov/37587577/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff = 20230818021019&amp;v=2.17.9.post6+86293ac<description>没有摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 8 月 22 日；82(8):671-673.doi:10.1016/j.jacc.2023.05.060。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37587577/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37587577</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.05.060>10.1016/j.jacc.2023.05.060</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37587577</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:creator>乔纳森·H·金</dc:creator><dc:date>2023-08-17</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>Competitive Sports Participation for Athletes With Genetic Heart Disease: A Whole New Ballgame</dc:title><dc:identifier> pmid:37587577</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.060</dc:identifier></item><item><title> Return-to-Play for Elite Athletes With Genetic Heart Diseases Predisposing to Sudden Cardiac Death</title><link/> https://pubmed.ncbi.nlm.nih.gov/37587576/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230818021019&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: This is the first study describing the experience of athletes with a known SCD-predisposing GHD who are competing at the elite level. After careful evaluation, risk stratification, and tailoring of their GHD therapy, RTP following SDM appears associated with low, nonfatal events rates at elite levels of sport. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol. 2023 Aug 22;82(8):661-670. doi: 10.1016/j.jacc.2023.05.059.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: People diagnosed with genetic heart diseases (GHDs) associated with sudden cardiac death (SCD) have historically been restricted from competitive sports. Recent data documenting return-to-play (RTP) experiences following shared decision making (SDM) suggest that cardiac event rates for athletes with a GHD are lower than previously described, thereby suggesting an opportunity to reconsider this paradigm. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: The purpose of this study was to evaluate clinical outcomes among National Collegiate Athletic Association Division I university and professional athletes diagnosed with a GHD. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: A multicenter retrospective analysis was performed to examine demographics, clinical characteristics, RTP outcomes, and cardiac events among elite athletes with a GHD. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: A total of 76 elite (66%, Division I, 34% professional) athletes (age 19.9 ± 5 years, 28% women) diagnosed with a GHD (hypertrophic cardiomyopathy [53%], long QT syndrome, long QT syndrome [26%]) comprise this cohort. Most athletes were asymptomatic (48 of 76, 63%) before diagnosis and had their GHD detected during routine preparticipation cardiovascular screening. Most athletes (55 of 76, 72%) were initially disqualified from their sport but subsequently opted for unrestricted RTP after comprehensive clinical evaluation and SDM. To date, (mean follow-up 7 ± 6 years), only 1 exercise-related (1.3%) and 2 nonexercise-related GHD-associated adverse cardiac events occurred. There have been no fatalities during follow-up. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: This is the first study describing the experience of athletes with a known SCD-predisposing GHD who are competing at the elite level. After careful evaluation, risk stratification, and tailoring of their GHD therapy, RTP following SDM appears associated with low, nonfatal events rates at elite levels of sport.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37587576/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37587576</a> | DOI: <a href=https://doi.org/10.1016/j.jacc.2023.05.059>10.1016/j.jacc.2023.05.059</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37587576</guid><pubDate> Thu, 17 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Katherine A Martinez</dc:creator><dc:creator> J Martijn Bos</dc:creator><dc:creator> Aaron L Baggish</dc:creator><dc:creator> Dermot M Phelan</dc:creator><dc:creator> Kathryn E Tobert</dc:creator><dc:creator> Darrel B Newman</dc:creator><dc:creator> Erica Scherer</dc:creator><dc:creator> Bradley J Petek</dc:creator><dc:creator> Michael J Ackerman</dc:creator><dc:creator> Matthew W Martinez</dc:creator><dc:date> 2023-08-17</dc:date><dc:source> Journal of the American College of Cardiology</dc:source><dc:title> Return-to-Play for Elite Athletes With Genetic Heart Diseases Predisposing to Sudden Cardiac Death</dc:title><dc:identifier> pmid:37587576</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.05.059</dc:identifier></item><item><title> Future research with advanced imaging technology and biomarkers</title><link/> https://pubmed.ncbi.nlm.nih.gov/37587554/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230818021019&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 17:ehad530. doi: 10.1093/eurheartj/ehad530. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37587554/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37587554</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad530>10.1093/eurheartj/ehad530</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37587554</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Fabrizio Montecucco</dc:creator><dc:creator> Thomas H Schindler</dc:creator><dc:date> 2023-08-16</dc:date><dc:source> European heart journal</dc:source><dc:title> Future research with advanced imaging technology and biomarkers</dc:title><dc:identifier> pmid:37587554</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad530</dc:identifier></item><item><title> Inflammation in acute myocardial infarction: the good, the bad and the ugly</title><link/> https://pubmed.ncbi.nlm.nih.gov/37587550/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230818021019&amp;v=2.17.9.post6+86293ac<description> Convergent experimental and clinical evidence have established the pathophysiological importance of pro-inflammatory pathways in coronary artery disease. Notably, the interest in treating inflammation in patients suffering acute myocardial infarction (AMI) is now expanding from its chronic aspects to the acute setting. Few large outcome trials have proven the benefits of anti-inflammatory therapies on cardiovascular outcomes by targeting the residual inflammatory risk (RIR), ie the smouldering... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 17:ehad486. doi: 10.1093/eurheartj/ehad486. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Convergent experimental and clinical evidence have established the pathophysiological importance of pro-inflammatory pathways in coronary artery disease. Notably, the interest in treating inflammation in patients suffering acute myocardial infarction (AMI) is now expanding from its chronic aspects to the acute setting. Few large outcome trials have proven the benefits of anti-inflammatory therapies on cardiovascular outcomes by targeting the residual inflammatory risk (RIR), ie the smouldering ember of low-grade inflammation persisting in the late phase after AMI. However, these studies have also taught us about potential risks of anti-inflammatory therapy after AMI, particularly related to impaired host defence. Recently, numerous smaller-scale trials have addressed the concept of targeting a deleterious flare of excessive inflammation in the early phase after AMI. Targeting different pathways and implementing various treatment regimens, those trials have met with varied degrees of success. Promising results have come from those studies intervening early on the interleukin-1 and -6 pathways. Taking lessons from such past research may inform an optimized approach to target post-AMI inflammation, tailored to spare &#39;The Good&#39; (repair and defence) while treating &#39;The Bad&#39; (smouldering RIR) and capturing &#39;The Ugly&#39; (flaming early burst of excess inflammation in the acute phase). Key constituents of such a strategy may read as follows: select patients with large pro-inflammatory burden (ie large AMI); initiate treatment early (eg ≤12 h post-AMI); implement a precisely targeted anti-inflammatory agent; follow through with a tapering treatment regimen. This approach warrants testing in rigorous clinical trials.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37587550/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230818021019&v=2.17.9.post6+86293ac">37587550</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad486>10.1093/eurheartj/ehad486</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37587550</guid><pubDate> Wed, 16 Aug 2023 06:00:00 -0400</pubDate><dc:creator> Michael A Matter</dc:creator><dc:creator> Francesco Paneni</dc:creator><dc:creator> Peter Libby</dc:creator><dc:creator> Stefan Frantz</dc:creator><dc:creator> Barbara E Stähli</dc:creator><dc:creator> Christian Templin</dc:creator><dc:creator> Alessandro Mengozzi</dc:creator><dc:creator> Yu-Jen Wang</dc:creator><dc:creator> Thomas M Kündig</dc:creator><dc:creator> Lorenz Räber</dc:creator><dc:creator> Frank Ruschitzka</dc:creator><dc:creator> Christian M Matter</dc:creator><dc:date> 2023-08-16</dc:date><dc:source> European heart journal</dc:source><dc:title> Inflammation in acute myocardial infarction: the good, the bad and the ugly</dc:title><dc:identifier> pmid:37587550</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad486</dc:identifier></item></channel></rss>